GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
STOCK OF THE DAY- ERasca.
$3.58
Erasca initiated with a Buy at Goldman Sachs 04:43 ERAS Goldman S
(old news)
we reported four responses in nine patients with BRAF-driven tumors to either monotherapy ERAS-007 or ERAS-601. Three of these responses were in tumors with BRAF Class 2 or 3 alterations, including a confirmed response to monotherapy SHP2 inhibition in a patient with a BRAF Class 3 alteration, which is dependent on upstream receptor tyrosine kinase activation. We look forward to exploring the potential to address the high unmet need in these BRAF subtypes, which have no approved targeted therapies and represent up to 25% of all BRAF-driven tumors."
Dec 20---> Erasca announces first patient dosed in HERKULES-1 Phase 1b trial 12/20 ERAS Erasca announced dosing of the first patient in the HERKULES-1 Phase 1b trial evaluating ERK1/2 inhibitor ERAS-007 in combination with SHP2 inhibitor ERAS-601 in patients with RAS/MAPK pathway-altered solid tumors.
Feb 3->Erasca upgraded to Overweight from Equal Weight at Morgan Stanley 02/03 ERAS Morgan Stanley analyst Jeffrey Hung upgraded Erasca to Overweight from Equal Weight with a $15 price target. The analyst says the company recently bolstered its pipeline with naporafenib and has multiple data readouts expected this year. The firm now has greater confidence in Erasca's pipeline both on potential time to market and probability of success with the addition of naporafenib.
IDEA #3 ERAS $3.60
$3.58
Erasca initiated with a Buy at Goldman Sachs 04:43 ERAS Goldman S
(old news)
we reported four responses in nine patients with BRAF-driven tumors to either monotherapy ERAS-007 or ERAS-601. Three of these responses were in tumors with BRAF Class 2 or 3 alterations, including a confirmed response to monotherapy SHP2 inhibition in a patient with a BRAF Class 3 alteration, which is dependent on upstream receptor tyrosine kinase activation. We look forward to exploring the potential to address the high unmet need in these BRAF subtypes, which have no approved targeted therapies and represent up to 25% of all BRAF-driven tumors."
Dec 20---> Erasca announces first patient dosed in HERKULES-1 Phase 1b trial 12/20 ERAS Erasca announced dosing of the first patient in the HERKULES-1 Phase 1b trial evaluating ERK1/2 inhibitor ERAS-007 in combination with SHP2 inhibitor ERAS-601 in patients with RAS/MAPK pathway-altered solid tumors.
Feb 3->Erasca upgraded to Overweight from Equal Weight at Morgan Stanley 02/03 ERAS Morgan Stanley analyst Jeffrey Hung upgraded Erasca to Overweight from Equal Weight with a $15 price target. The analyst says the company recently bolstered its pipeline with naporafenib and has multiple data readouts expected this year. The firm now has greater confidence in Erasca's pipeline both on potential time to market and probability of success with the addition of naporafenib.
IDEA #3 ERAS $3.60
Hhahahahahahahahh
Welcome to GBA.... that's how Stoney rolls.
He'll post at 10:30 an all-caps "WINNER WINNER"
Of course this is one of the best names in Biotech.
I have never researched them.
Werewolf Therapeutics doses first patient in Phase 1 study of WTX-330 07:32 HOWL
I have never researched them.
Werewolf Therapeutics doses first patient in Phase 1 study of WTX-330 07:32 HOWL
Hhahahahahahahahh
Welcome to GBA.... that's how Stoney rolls.
He'll post at 10:30 an all-caps "WINNER WINNER"
I don't look at the pre I have no idea what these stocks are doing.
But if you see one up 10% and you have soft open maybe buy it up 5% DUMB ASS
After all of this time have I not taught you all not to watch the fast movers.
I had my time when that's all I did- scan for big movers and scalp and then I realized wow I'm a follower.
I had my time when that's all I did- scan for big movers and scalp and then I realized wow I'm a follower.
And maybe buy it again at unch, -5%, -10%. You’re taking credit based upon prior closes. lol clown shoes.
You're up early.
You must have a big position on the line.
G/L with it, whatever it is.
Liberty Formula One initiated with a Peer Perform at Wolfe Research » 06:09 FWONK
I've been circling this name again. There are two classes of stock and we had been using the one ending in Y== Wolf used the one ending on K... can't remember for the life of me what the difference is.
I've been circling this name again. There are two classes of stock and we had been using the one ending in Y== Wolf used the one ending on K... can't remember for the life of me what the difference is.